Women's Health

Cytoreductive surgery before chemotherapy led to significant and clinically meaningful OS and PFS benefits for women with recurrent ovarian cancer, according to a phase 3 study published in The New England Journal of Medicine.

The FDA granted priority review to olaparib for adjuvant treatment of certain patients with high-risk breast cancer.

The FDA approved the imaging drug pafolacianine to help surgeons identify ovarian cancer lesions.

Postmenopausal women participating in 4 hours of standing plus 3 hours of walking per day had improved insulin sensitivity similar to those who engaged in 1 hour of moderate to vigorous exercise, according to study findings.

Measurement of residual cancer burden served as both an accurate and consistent indicator of prognosis across breast cancer subtypes, according to an analysis of data from the randomized I-SPY2 trial published in JAMA Oncology.

Genetic testing for breast cancer has evolved substantially since its inception nearly 30 years ago, according to a speaker at Chemotherapy Foundation Symposium.

Women with cystic fibrosis have higher rates of pulmonary exacerbations compared with men, with differences appearing early in life, researchers reported at the virtual North American Cystic Fibrosis Conference.

Studies used to determine nutritional recommendations in the U.S. and Canada often lack women, including those who are pregnant, according to findings published in Science Advances.

Increased use of neoadjuvant chemotherapy appeared associated with improvements in short-term mortality without sacrificing long-term survival in ovarian cancer, according to a comparative effectiveness research study in JAMA Oncology.

Breast cancer screening rates declined within 32 community health centers serving lower-income populations during the COVID-19 pandemic, according to an American Cancer Society study published in Cancer.